PHARVARIS NV (PHVS:NASDAQ)
$28.59 -0.19 (-0.6602%)
Analysed PHARVARIS NV (PHVS:NASDAQ) News Sources
Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors.
13-04-2026
fool.com
Texas Instruments upgraded, Circle downgraded: Wall Street's top analyst calls
09-04-2026
yahoo.com
Did Phase 3 Completion and 2025 Losses Just Shift Pharvaris’ (PHVS) Investment Narrative?
07-04-2026
yahoo.com
Pharvaris' Deucrictibant Could Be a Game Changer Pending Phase III Results, RBC Says
06-04-2026
yahoo.com
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
02-04-2026
yahoo.com
Does Pharvaris (PHVS) Have the Potential to Rally 59.93% as Wall Street Analysts Expect?
01-04-2026
yahoo.com
BioCryst Shares Remain Undervalued, RBC Says
25-03-2026
yahoo.com
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
20-03-2026
yahoo.com
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
18-03-2026
fool.com
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
18-03-2026
fool.com
What is the current price of PHARVARIS NV (PHVS:NASDAQ)?
The current price of PHARVARIS NV (PHVS:NASDAQ) is $28.59.
PHARVARIS NV (PHVS:NASDAQ) absolute price change since previous trading day?
The absolute price change of PHARVARIS NV (PHVS:NASDAQ) since the previous trading day is $-0.19.
PHARVARIS NV (PHVS:NASDAQ) percentage price change since previous trading day?
The percentage price change of PHARVARIS NV (PHVS:NASDAQ) since the previous trading day is -0.6602%.
What is the most recent average sentiment score for PHARVARIS NV (PHVS:NASDAQ)?
The most recent average sentiment score for PHARVARIS NV (PHVS:NASDAQ) is 56 out of 100.
What is the most recent average sentiment for PHARVARIS NV (PHVS:NASDAQ)?
The most recent sentiment for PHARVARIS NV (PHVS:NASDAQ) is .
SEC-8K** Filing Available For PHARVARIS NV (PHVS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.